Diverging Outcomes of Myosin Inhibitors in Cardiomyopathy

Cytokinetics (CYTK)'s Myqorzo (aficamten), a cardiac myosin inhibitor, improved KCCQ scores by 11.4 points in 517 patients with non-obstructive hypertrophic cardiomyopathy (nHCM) in the 36-week ACACIA-HCM Phase 3 trial, outperforming placebo's 8.4-point improvement. Maximal oxygen uptake increased by 0.64 mL/kg/min, but the proportion of patients with left ventricular ejection fraction below 50% was 10.5%, higher than the 0.8% in the placebo group. The drug received FDA approval for obstructive HCM on December 19, 2025, with a planned nHCM label expansion in Q4 2026. Competitor Camzyos (mavacamten) from Bristol Myers Squibb (BMY), targeting the same pathway, failed to meet its primary endpoint in the Phase 3 ODYSSEY-HCM trial for nHCM, amplifying Myqorzo's differentiation.

RNAi Leads in Triglyceride Therapy

Arrowhead Pharmaceuticals (ARWR)'s Redemplo (plozasiran), an APOC3-targeting siRNA, reduced triglycerides by 79% and 81% in the 757-patient SHASTA-3 and -4 Phase 3 trials, respectively, and cut acute pancreatitis events by 78%. Redemplo received FDA approval for familial chylomicronemia syndrome on November 18, 2025, with a planned label expansion for severe hypertriglyceridemia by late 2026. Ionis Pharmaceuticals (IONS)'s APOC3 siRNA ION775 reduced triglycerides by up to 68.4% at six months post-single dose in Phase 1, advancing to Phase 2. CRISPR Therapeutics (CRSP)'s ANGPTL3 gene editor CTX310 maintained 79% ANGPTL3, 48% triglyceride, and 53% LDL-C reductions at one year in the highest dose of Phase 1a, suggesting potential for one-time treatment beyond quarterly or semi-annual dosing.

Heart Failure and Inflammation Pipelines Face Validation

Medera's SRD-002, a one-time gene therapy delivering SERCA2a via AAV1 vector, met the normalization criteria for cardiac filling pressure in 8 out of 10 HFpEF patients in Phase 1/2a at 12 months, with an average 17.8-point KCCQ improvement. AstraZeneca (AZN)'s oral RXFP1 agonist AZD5462 showed hemodynamic benefits in 375 patients in the Phase 2b LUMINARA trial, but the 20mg dose in the severe HFrEF group failed to meet statistical significance for end-systolic volume index. Novartis (NVS)'s IL-6 antibody pacibekitug, acquired through Tourmaline Bio, reduced hs-CRP by 76–85% with quarterly dosing in Phase 2. However, Novo Nordisk (NVO)'s competing IL-6 antibody ziltivekimab failed to reduce major cardiovascular events in the 6,300+ patient ZEUS Phase 3 trial, highlighting that biomarker reduction alone may not justify late-stage development.

Large Phase 3 Failures Reveal Commercialization Barriers

AstraZeneca and Ionis' Wainua (eplontersen), an antisense oligonucleotide targeting TTR, is FDA-approved for hereditary ATTR polyneuropathy but failed to reduce cardiovascular death or recurrent events in the 1,400+ patient CARDIO-TTRansform Phase 3 trial for ATTR cardiomyopathy. Bristol Myers Squibb and Johnson & Johnson (JNJ)'s FXIa inhibitor milvexian showed a 5.4% rate of cardiovascular death, myocardial infarction, or ischemic stroke in the 14,000+ patient LIBREXIA-ACS trial, exceeding the 5.1% in the placebo group. Both failures underscore the difficulty of demonstrating efficacy in trials adding new drugs on top of standard-of-care antiplatelet and antiarrhythmic therapies. The race for the $37.3 billion global anticoagulant market and $20.5 billion heart failure drug market is increasingly driven by the ability to design trials that prove clinical event reduction, rather than novel mechanisms.